echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The efficacy is controversial! The European 2000s Instigation Medical Association does not recommend Redsiwe for such patients

    The efficacy is controversial! The European 2000s Instigation Medical Association does not recommend Redsiwe for such patients

    • Last Update: 2021-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Compiled as the first approved COVID-19 treatment in the United States, Remdesivir (now known as Veklury) is probably the most successful COVID-19 drug to date.
    , however, there seem to be questions about Veklury's specific efficacy.
    , the European 2000s said it did not recommend the drug for patients in intensive care units.
    Jozef Kesecioglu, president of the European Society of Intensive Care Medicine, told Reuters in an interview that Redsyvir "is currently listed as a drug that is not recommended for routine use in COVID-19 patients in intensive care," according to a large World Health Organization study.
    Kesecioglu said the team and the U.S. Serious Medical Association plan to make the recommendation in an upcoming paper on coVID-19 drugs, after experts said there was not enough data to recommend the drug in patients.
    , Gilead said in a Reuters response statement, "We are confident that front-line physicians will recognize veklury's clinical benefits based on reliable evidence from multiple randomized controlled studies."
    thousands of members of the European Society of Intensive Care Medicine covering more than 100 countries or regions.
    the society's recommendations do not require doctors to fully follow, the organization's position may reduce the overall clinical use of ryxive, Reuters reported.
    Veklury received FDA approval in October for COVID-19 patients who needed hospitalization.
    's approval is based on the final results of three randomized controlled trials, including the recently published National Institute of Allergy and Infectious Diseases (NIAID) double-blind placebo-controlled Phase 3 ACTT-1 trial, which showed that Veklury therapy had clinically significant improvements in multiple outcome evaluations compared to placebo in COVID-19 hospitalized patients.
    based on the strength of these data, Veklury has become the standard treatment for COVID-19 inpatients.
    , just a week before FDA approval, a major World Health Organization study found the drug's efficacy was "small or ineffective."
    Gilead hit back at the findings, saying the data had not been "reviewed as rigorously as necessary to allow for constructive scientific discussion, especially given the limitations of the experimental design."
    " in addition, because the trial prioritizes the efficacy of the drug's widespread use, there are too many variables in the patient population participating in the trial, so "it is not clear whether the findings can be drawn from the findings."
    despite the controversial efficacy of Redsyve, there is a clinical demand for the drug throughout the global pandemic, leading to a shortage of supplies.
    reported sales of $873 million last quarter.
    source: After WHO trial failure, aned medical group advises against Gilead's remdesivir in COVID critical care: Reuters
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.